{"id":"https://openalex.org/W2583522154","doi":"https://doi.org/10.1182/blood.v120.21.159.159","title":"Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Curative of Double Hit Diffuse Large B-Cell Lymphoma in Mice","display_name":"Alisertib Added to Rituximab and Vincristine Is Synthetic Lethal and Curative of Double Hit Diffuse Large B-Cell Lymphoma in Mice","publication_year":2012,"publication_date":"2012-11-16","ids":{"openalex":"https://openalex.org/W2583522154","doi":"https://doi.org/10.1182/blood.v120.21.159.159","mag":"2583522154"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v120.21.159.159","doi":"https://doi.org/10.1182/blood.v120.21.159.159","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v120.21.159.159","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101638085","display_name":"Daruka Mahadevan","orcid":"https://orcid.org/0000-0002-7129-5593","observed_orcids":["https://orcid.org/0000-0002-7129-5593"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Daruka Mahadevan","raw_affiliation_strings":["Research, The West Clinic, Memphis, TN, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Research, The West Clinic, Memphis, TN, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5101638085"],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.41979584,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"120","issue":"21","first_page":"159","last_page":"159"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9789999723434448,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10185","display_name":"Lymphoma Diagnosis and Treatment","score":0.9789999723434448,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0035000001080334187,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10492","display_name":"Microtubule and mitosis dynamics","score":0.003100000089034438,"subfield":{"id":"https://openalex.org/subfields/1307","display_name":"Cell Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alisertib","display_name":"alisertib","score":0.9620000123977661},{"id":"https://openalex.org/keywords/mln8237","display_name":"MLN8237","score":0.9340000152587891},{"id":"https://openalex.org/keywords/aurora-kinase-inhibitors","display_name":"Aurora kinase inhibitors","score":0.6010000109672546},{"id":"https://openalex.org/keywords/synthetic-lethality","display_name":"synthetic lethality","score":0.902999997138977},{"id":"https://openalex.org/keywords/rituximab","display_name":"rituximab","score":0.972000002861023},{"id":"https://openalex.org/keywords/vincristine","display_name":"vincristine","score":0.9990000128746033},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5019999742507935},{"id":"https://openalex.org/keywords/myc-translocation","display_name":"MYC translocation","score":0.6690000295639038},{"id":"https://openalex.org/keywords/bcl2-translocation","display_name":"BCL2 translocation","score":0.9810000061988831},{"id":"https://openalex.org/keywords/relapsed-refractory-lymphoma","display_name":"relapsed/refractory lymphoma","score":0.8600000143051147},{"id":"https://openalex.org/keywords/tumor-regression","display_name":"tumor regression","score":0.550000011920929},{"id":"https://openalex.org/keywords/xenograft-models","display_name":"xenograft models","score":0.7599999904632568},{"id":"https://openalex.org/keywords/apoptosis","display_name":"apoptosis","score":0.5019999742507935},{"id":"https://openalex.org/keywords/p53","display_name":"p53","score":0.4959999918937683}],"concepts":[{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.7034432291984558},{"id":"https://openalex.org/C2779429289","wikidata":"https://www.wikidata.org/wiki/Q408977","display_name":"Vincristine","level":4,"score":0.6417548060417175},{"id":"https://openalex.org/C2778559949","wikidata":"https://www.wikidata.org/wiki/Q2626074","display_name":"Diffuse large B-cell lymphoma","level":3,"score":0.6240369081497192},{"id":"https://openalex.org/C2777525834","wikidata":"https://www.wikidata.org/wiki/Q268713","display_name":"Mantle cell lymphoma","level":3,"score":0.6229218244552612},{"id":"https://openalex.org/C2777537477","wikidata":"https://www.wikidata.org/wiki/Q17847411","display_name":"BCL6","level":5,"score":0.5566415190696716},{"id":"https://openalex.org/C20552341","wikidata":"https://www.wikidata.org/wiki/Q4822632","display_name":"Aurora inhibitor","level":4,"score":0.5476951599121094},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.46094971895217896},{"id":"https://openalex.org/C2780653079","wikidata":"https://www.wikidata.org/wiki/Q412323","display_name":"Rituximab","level":3,"score":0.4458520710468292},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.41769570112228394},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4012100100517273},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.3504748046398163},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3462301790714264},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.324310839176178},{"id":"https://openalex.org/C2778453870","wikidata":"https://www.wikidata.org/wiki/Q188930","display_name":"B cell","level":3,"score":0.2362404465675354},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.22518542408943176},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.21228116750717163},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.1671622395515442},{"id":"https://openalex.org/C2776755627","wikidata":"https://www.wikidata.org/wiki/Q408524","display_name":"Cyclophosphamide","level":3,"score":0.15520071983337402},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.11496108770370483},{"id":"https://openalex.org/C96926380","wikidata":"https://www.wikidata.org/wiki/Q1737968","display_name":"Germinal center","level":4,"score":0.10572364926338196},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v120.21.159.159","doi":"https://doi.org/10.1182/blood.v120.21.159.159","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v120.21.159.159","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7097415684","https://openalex.org/W2071817259","https://openalex.org/W2625442315","https://openalex.org/W2753386331","https://openalex.org/W2979551512","https://openalex.org/W2594757467","https://openalex.org/W2077212219","https://openalex.org/W2979632116","https://openalex.org/W2564945551","https://openalex.org/W2085771242"],"abstract_inverted_index":{"Abstract":[0],"159":[1],"About":[2],"one-third":[3],"of":[4,17,30,47,57,61,67,184,210,230,312,318,330,347,427],"diffuse":[5],"large":[6],"B-cell":[7],"lymphoma":[8,106],"(DLBCL)":[9],"patients":[10],"develop":[11],"relapsed/refractory":[12],"disease,":[13],"a":[14,45,98,103,281,352,392,416],"major":[15],"cause":[16],"morbidity":[18],"and":[19,32,42,74,97,130,144,149,156,170,177,203,234,268,278,293,309,340],"mortality.":[20],"Of":[21],"DLBCL,":[22],"5%":[23],"are":[24,44,152],"double-hit":[25],"lymphomas":[26,369],"(DHLs)":[27],"with":[28,38,109,162,205,252,275,297],"translocations":[29],"MYC":[31],"BCL2":[33],"characterized":[34],"by":[35,371,379,403],"poor":[36],"outcomes":[37],"R-CHOP.":[39],"Auroras":[40,68],"(A":[41],"B)":[43],"family":[46],"mitotic":[48,59],"oncogenic":[49],"serine/threonine":[50],"kinases":[51],"required":[52],"for":[53,189],"high":[54],"fidelity":[55],"regulation":[56],"the":[58,62,133,316,327],"phase":[60],"cell":[63,105,111,127,167],"cycle.":[64],"Aberrant":[65],"over-expression":[66],"leads":[69],"to":[70,76,174,227,237,289,325,335,349,429],"genetic":[71,113],"instability,":[72],"polyploidy":[73],"resistance":[75],"microtubule":[77],"targeted":[78],"agents.":[79],"Previously":[80],"we":[81],"showed":[82,186,271],"Aurora":[83,331],"inhibitor":[84],"(MLN8237,":[85],"alisertib)":[86],"[M]":[87],"plus":[88,91],"vincristine":[89],"[V]":[90],"rituximab":[92],"[R]":[93],"is":[94,136,142,357],"synthetic":[95],"lethal":[96],"potential":[99],"curative":[100],"therapy":[101,161],"in":[102,145,285,363,391,415],"mantle":[104],"model":[107,183],"(Granta-519)":[108],"several":[110],"cycle":[112,168],"defects":[114],"[t":[115],"(11;14)],":[116],"ATM":[117],"(haploinsufficient),":[118],"p16/p14":[119],"(Del)]":[120],"but":[121,241],"p53":[122,154],"(WT).":[123],"We":[124],"evaluated":[125],"ABC-DLBCL":[126,394,418],"lines":[128],"TMD-8":[129],"U-2932":[131,185,393,417],"where":[132],"BCR/NF-kB":[134],"pathway":[135],"constitutively":[137],"active.":[138],"In":[139,247],"TMD-8,":[140],"CD79B":[141],"mutated":[143],"U-2932,":[146],"Bcl2":[147],"[3q27]":[148],"Bcl6":[150],"[18q21]":[151],"amplified,":[153],"(mutated)":[155],"c-Myc":[157],"over-expressed":[158],"[DHL].":[159],"Triple":[160],"MVR":[163,249,279,390,414],"abolished":[164],"proliferation,":[165],"disrupted":[166],"processes":[169],"induced":[171,221],"apoptosis":[172],"compared":[173,288],"single":[175],"agent":[176],"doublet":[178],"treatments.":[179],"A":[180],"Mouse":[181,396,420],"xenograft":[182],"modest":[187],"activity":[188],"M":[190],"(30":[191],"mg":[192],"kg,":[193],"PO,":[194],"QD,":[195],"3":[196],"weeks),":[197],"V":[198,292],"(0.375":[199],"mg/kg,":[200,217],"IV,":[201,218],"Q1Wx3)":[202,219],"MV":[204,294,350],"tumor":[206,238],"growth":[207],"inhibition":[208,332],"(TGI)":[209],"\u223c10%":[211],"(p=0.01)":[212,225],"respectively.":[213],"However,":[214],"R":[215,336,348],"(10":[216],"alone":[220],"\u223c":[222],"50%":[223],"TGI":[224],"due":[226],"effective":[228],"targeting":[229],"Bcl2.":[231],"Doublets":[232],"MR":[233],"VR":[235,277,341],"led":[236],"regression":[239],"(TR),":[240],"relapse":[242],"soon":[243],"after":[244,257],"stopping":[245,258],"therapy.":[246,259],"contrast,":[248],"demonstrated":[250],"TR":[251],"no":[253],"relapses":[254],">40":[255],"days":[256],"All":[260],"treatments":[261],"were":[262],"well":[263],"tolerated":[264],"(no":[265],"weight":[266],"loss)":[267],"Kaplan-Meier":[269,377,401],"analysis":[270],"that":[272,356],"mice":[273],"treated":[274],"MR,":[276,387,411],"had":[280],"statistically":[282],"significant":[283],"improvement":[284],"overall":[286],"survival":[287],"control,":[290],"M,":[291],"(p<0.0001).":[295],"Moreover,":[296],"MVR,":[298],"OS":[299],"was":[300],"100%":[301],"(Figure":[302],"1).":[303],"Gene":[304],"expression":[305],"profiling,":[306],"RT-PCR,":[307],"IHC":[308],"Western":[310],"blotting":[311],"harvested":[313],"tumors":[314],"at":[315],"end":[317],"treatment":[319],"(3":[320],"weeks)":[321],"has":[322],"been":[323],"interrogated":[324],"ascertain":[326],"mechanistic":[328],"role":[329],"when":[333],"added":[334],"[R":[337],"Vs":[338,343],"MR]":[339],"[VR":[342],"MVR].":[344],"Thus,":[345],"addition":[346],"represents":[351],"novel":[353],"therapeutic":[354],"strategy":[355],"currently":[358],"under":[359],"clinical":[360],"trial":[361],"evaluation":[362],"aggressive":[364],"B-NHL":[365],"including":[366],"double":[367],"hit":[368],"sponsored":[370],"Millennium":[372],"Pharmaceuticals":[373],"(C14011).":[374],"Figure":[375,399],"1:":[376],"Survival":[378,402],"Treatment:":[380,404],"MLN8237":[381,405],"(M),":[382,406],"Rituximab":[383,407],"(R),":[384,408],"Vincristine":[385,409],"(V),":[386,410],"MV,":[388,412],"VR,":[389,413],"SCID":[395,419],"Xenograft":[397,421],"Model":[398,422],"1:.":[400],"Disclosures:":[423],"No":[424],"relevant":[425],"conflicts":[426],"interest":[428],"declare.":[430]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-02-10T00:00:00"}